For medical device manufacturers, a reliable Quality Management System (QMS) is the foundation of safe products, faster approvals, and sustainable market access. Yet aligning your QMS with the European Union Medical Device Regulation (MDR) and the US Food and Drug Administration (FDA) Quality System Regulation (QSR, 21 CFR Part 820) is one of the biggest challenges global companies face.
The traditional approach of building separate systems for each jurisdiction is inefficient and increases the risk of inconsistencies, audit findings, and costly delays. A harmonised approach allows you to maintain one streamlined QMS that meets all major requirements, including MDR, FDA QSR, and UK Medical Device Regulations overseen by the MHRA.
This guide outlines five strategies to help manufacturers achieve a harmonised, future-proof QMS. Each strategy draws on international standards, best practices, and our experience supporting companies of all sizes through regulatory transitions.
1. Build on ISO 13485 and Use MDSAP
The best way to align your QMS globally is to start with ISO 13485:2016 as the backbone. This internationally recognised standard is accepted across multiple jurisdictions and provides a structured, risk-based framework that maps directly to MDR and FDA QSR requirements.
- Design Controls: ISO 13485 clauses on design and development feed directly into MDR Annex II and the FDA’s Design History File requirements.
- Risk Management: ISO 13485 requires risk-based processes that are closely aligned with ISO 14971 and MDR expectations.
- Post-Market Surveillance: The standard provides mechanisms that support both FDA vigilance and MDR’s proactive PMS model.
Beyond ISO 13485, the Medical Device Single Audit Program (MDSAP) is invaluable for manufacturers seeking global market access. An MDSAP audit is recognised in the US, Canada, Brazil, Australia, and Japan. For the FDA, an MDSAP certificate can substitute for a routine QMS inspection, significantly reducing audit burden.
At Russell Regulatory, we support manufacturers with ISO 13485 implementation, QMS gap analysis, and MDSAP preparation, ensuring your QMS is optimised for compliance and efficiency.
Related Reading: The Importance of Quality Management Systems for UK Medical Devices
2. Integrate Risk Management Across the Lifecycle
Risk management for medical devices is one of the clearest areas where MDR goes further than the FDA. While the FDA requires risk analysis within design and manufacturing processes, MDR demands a continuous, lifecycle-based risk management system embedded in every aspect of the QMS.
Key differences to consider:
- MDR: Risk management is proactive, ongoing, and must be demonstrated throughout the device lifecycle. It ties directly into clinical evaluation, PMS, and CAPA.
- FDA QSR: Risk activities are required, but not always to the same prescriptive depth.
By adopting MDR’s higher standard, anchored in ISO 14971:2019, medical device manufacturers cover both sets of requirements while building a defensible, regulator-friendly system. This means:
- Feeding post-market data (complaints, vigilance reports, PMS findings) back into the risk management file.
- Ensuring supplier controls incorporate risk assessment.
- Treating CAPA as an extension of risk reduction.
At Russell Regulatory Consultants, we help manufacturers implement secure, ISO 14971-aligned risk processes, ensuring compliance and stronger product safety throughout the lifecycle. Need help embedding risk management into your QMS? Our consultants can support implementation from gap analysis to ISO 14971 integration. Book a free call today!
Related Reading: A Step-by-Step Overview of MHRA Registration for Your Medical Device
3. Unify Post-Market Surveillance (PMS) and Clinical Follow-Up (PMCF)
In the post-market phase, MDR introduces significant new obligations compared to the FDA. Under MDR:
- PMS systems are mandatory, with proactive monitoring and analysis of device performance.
- PMCF plans are required for most devices, mandating the ongoing collection of clinical data to confirm safety and performance.
In contrast, the FDA’s system is more reactive, requiring complaint handling, vigilance reporting, and recalls where necessary.
For manufacturers, the smartest approach is to design one unified PMS framework that meets MDR’s higher bar. This single system will inherently satisfy FDA requirements while giving manufacturers valuable real-world insights into device performance.
A harmonised PMS/PMCF system should include:
- Standardised complaint handling procedures that feed into risk management.
- A CAPA process that addresses root causes and documents corrective action.
- Proactive clinical data collection includes registries, surveys, or extended clinical follow-ups.
- Clear escalation pathways for reporting adverse events to regulators (MHRA, FDA, Notified Bodies).
Our team works with clients to design PMS/PMCF frameworks that integrate MDR, FDA, and MHRA expectations, turning compliance into a source of business intelligence.
Related Reading: New Post-Market Surveillance Requirements for Medical Devices UK in 2025
4. Make Documentation and Training Audit-Ready
Technical documentation is the backbone of compliance. Both MDR and FDA QSR place heavy emphasis on documentation and record-keeping:
- MDR: Requires comprehensive Technical Documentation (Annex II/III).
- FDA: Requires a Design History File (DHF) and Device Master Record (DMR).
The most efficient approach is to maintain a single master documentation system that can be adapted for each regulator’s format. This ensures information is always complete, accurate, and audit-ready.
Equally important is training management. Regulators expect to see documented evidence that staff understand their responsibilities and are competent to perform them. Training records are often one of the first things requested in audits.
Best practices include:
- Maintaining a controlled training matrix linked to each QMS procedure.
- Documenting refresher training for regulatory updates.
- Ensuring new employees are trained before engaging in regulated activities.
Related Reading: The Value of Medical Device Regulatory Intelligence for Market Access Success
5. Partner with Experts for Gap Analysis and Ongoing Support
Even the best internal teams face challenges in keeping up with regulatory changes. The final strategy is to recognise the value of partnering with experienced regulatory consultants who can provide:
- QMS gap analysis against ISO 13485, MDR, and FDA requirements.
- Remediation plans that prioritise fixes before audits or submissions.
- Internal audits to prepare teams for Notified Body, FDA, or MHRA inspections.
- Strategic guidance for integrating new requirements without disrupting operations.
A trusted partner offers technical expertise and an outside perspective, helping identify weaknesses that internal teams may overlook. The investment reduces compliance risk and frees internal resources to focus on product development and innovation.
Related Reading: The Essential Guide to UK and EU Medical Device Post-Market Surveillance for 2025
Your Path to Simplified Compliance
Aligning your QMS with MDR, FDA, and other global frameworks is complex, but the payoff is enormous. A harmonised QMS reduces duplication, strengthens audit readiness, and creates a foundation for continuous improvement.
Manufacturers can achieve compliance by building on ISO 13485, embedding lifecycle risk management, unifying PMS systems, ensuring audit-ready documentation, and partnering with trusted experts, improving efficiency and market agility.
If you’d like to discuss how Russell Regulatory Consultants can support your QMS alignment, book a free call with our team today.
Article Sources
- US Food and Drug Administration. Quality System (QS) Regulation/Medical Device Current Good Manufacturing Practices (CGMP). 31st January 2024.
- US Food and Drug Administration. Design Control Guidance for Medical Device Manufacturers. Accessed 1st September 2025.
- ISO. ISO 14971:2019. Accessed 1st September 2025.
